Cediranib monotherapy in patients with advanced renal cell carcinoma: Results of a randomised phase II study

European Journal of Cancer

Volumn 48, Issue 4, 2012, Pages 527-537

  Mulders, Peter ^a   Hawkins, Robert ^b   Nathan, Paul ^c   De Jong, Igle ^d   Osanto, Susanne ^e   Porfiri, Emilio ^f   Protheroe, Andrew ^g   Van Herpen, Carla M L ^a   Mookerjee, Bijoyesh ^h   Pike, Laura ^h   Jürgensmeier, Juliane M ^h   Gore, Martin E ⁱ  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b CHRISTIE HOSPITAL   (United Kingdom)

^c MOUNT VERNON HOSPITAL   (United Kingdom)

^d UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^e LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^f UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^g CHURCHILL HOSPITAL   (United Kingdom)

^h ASTRAZENECA   (United Kingdom)

ⁱ ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

Cediranib; Monotherapy; Phase II; Renal cell carcinoma

Indexed keywords

CEDIRANIB; PLACEBO; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; ANOREXIA; ANTINEOPLASTIC ACTIVITY; BACKACHE; CANCER RECURRENCE; CONFERENCE PAPER; CONFUSION; CONSTIPATION; CONTROLLED STUDY; CROSSOVER PROCEDURE; DEHYDRATION; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSPHONIA; FATIGUE; FEMALE; HAND FOOT SYNDROME; HEADACHE; HUMAN; HYPERTENSION; KIDNEY CARCINOMA; LETHARGY; LIMB PAIN; MAJOR CLINICAL STUDY; MALE; METASTASIS; MONOTHERAPY; MYOPATHY; NAUSEA; OUTCOME ASSESSMENT; PARALLEL DESIGN; PHARMACODYNAMICS; PHASE 2 CLINICAL TRIAL; POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE; STOMATITIS; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR VOLUME;

AGED; ALGORITHMS; ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; DOUBLE-BLIND METHOD; FEMALE; HUMANS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; PLACEBOS; QUINAZOLINES; TREATMENT OUTCOME; TUMOR BURDEN;

EID: 84857052966     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2011.12.022     Document Type: Conference Paper

References (29)

1. A. Jemal, F. Bray, and M.M. Center Global cancer statistics CA Cancer J Clin 61 2011 69 90
2. B.I. Rini, and E.J. Small Biology and clinical development of vascular endothelial growth factor-targeted therapy in renal cell carcinoma J Clin Oncol 23 2005 1028 1043 (Pubitemid 46202321)
3. J. Ansari, J. Glaholm, R. McMenemin, N.D. James, and S.A. Hussain Recent advances and future directions in the management of metastatic renal cell carcinoma Anticancer Agents Med Chem 10 2010 225 235
4. S.R. Wedge, J. Kendrew, and L.F. Hennequin AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer Cancer Res 65 2005 4389 4400 (Pubitemid 40775678)
5. C.A. Heckman, T. Holopainen, and M. Wirzenius The tyrosine kinase inhibitor cediranib blocks ligand-induced vascular endothelial growth factor receptor-3 activity and lymphangiogenesis Cancer Res 68 2008 4754 4762
6. J. Drevs, P. Siegert, and M. Medinger Phase I clinical study of AZD2171, an oral vascular endothelial growth factor signaling inhibitor, in patients with advanced solid tumors J Clin Oncol 25 2007 3045 3054 (Pubitemid 47218051)
7. L.Q. Chow, and S.G. Eckhardt Sunitinib: from rational design to clinical efficacy J Clin Oncol 25 2007 884 896 (Pubitemid 350002890)
8. R. Kumar, V.B. Knick, and S.K. Rudolph Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity Mol Cancer Ther 6 2007 2012 2021 (Pubitemid 47052491)
9. S.M. Wilhelm, C. Carter, and L. Tang BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis Cancer Res 64 2004 7099 7109 (Pubitemid 39331023)
10. N. Yamamoto, T. Tamura, and N. Yamamoto Phase I, dose escalation and pharmacokinetic study of cediranib (RECENTIN), a highly potent and selective VEGFR signaling inhibitor, in Japanese patients with advanced solid tumors Cancer Chemother Pharmacol 64 2009 1165 1172
11. T.T. Batchelor, A.G. Sorensen, and E. di Tomaso AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients Cancer Cell 11 2007 83 95 (Pubitemid 46075199)
12. W. Fiedler, R. Mesters, and M. Heuser An open-label, Phase I study of cediranib (RECENTIN) in patients with acute myeloid leukemia Leuk Res 34 2010 196 202
13. M.H. Langenberg, C.M. van Herpen, and J. de Bono Effective strategies for management of hypertension after vascular endothelial growth factor signaling inhibition therapy: results from a phase II randomized, factorial, double-blind study of cediranib in patients with advanced solid tumors J Clin Oncol 27 2009 6152 6159
14. U.A. Matulonis, S. Berlin, and P. Ivy Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer J Clin Oncol 27 2009 5601 5606
15. S.A. Laurie, I. Gauthier, and A. Arnold Phase I and pharmacokinetic study of daily oral AZD2171, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with carboplatin and paclitaxel in patients with advanced non-small-cell lung cancer: the National Cancer Institute of Canada clinical trials group J Clin Oncol 26 2008 1871 1878
16. E. Chen, D. Jonker, and I. Gauthier Phase I study of cediranib in combination with oxaliplatin and infusional 5-fluorouracil in patients with advanced colorectal cancer Clin Cancer Res 15 2009 1481 1486
17. G. Goss, F.A. Shepherd, and S. Laurie A phase I and pharmacokinetic study of daily oral cediranib, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with cisplatin and gemcitabine in patients with advanced non-small cell lung cancer: a study of the National Cancer Institute of Canada Clinical Trials Group Eur J Cancer 45 2009 782 788
18. H. van Cruijsen, E.E. Voest, and C.J. Punt Phase I evaluation of cediranib, a selective VEGFR signalling inhibitor, in combination with gefitinib in patients with advanced tumours Eur J Cancer 46 2010 901 911
19. B. Escudier, C. Szczylik, and T. Eisen Randomized Phase III trial of the Raf kinase and VEGFR inhibitor sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma (RCC) J Clin Oncol 23 16S 2005 abst. 4510
20. P. Therasse, S.G. Arbuck, and E.A. Eisenhauer New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 2000 205 216
21. B. Escudier, J. Roigas, and S. Gillessen Phase II study of sunitinib administered in a continuous once-daily dosing regimen in patients with cytokine-refractory metastatic renal cell carcinoma J Clin Oncol 27 2009 4068 4075
22. B. Escudier, T. Eisen, and W.M. Stadler Sorafenib in advanced clear-cell renal-cell carcinoma N Engl J Med 356 2007 125 134 (Pubitemid 46089673)
23. O. Rixe, R.M. Bukowski, and M.D. Michaelson Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study Lancet Oncol 8 2007 975 984 (Pubitemid 47629888)
24. C.N. Sternberg, I.D. Davis, and J. Mardiak Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial J Clin Oncol 28 2010 1061 1068
25. S.S. Sridhar, M.J. Mackenzie, and S.J. Hotte AZD2171 (cediranib) is active in first line metastatic renal cell carcinoma (RCC): interim results of a phase II trial. A trial of the PMH Phase II consortium Mol Cancer Ther 6 2007 abst. A10
26. L. Vidal, H. Hirte, and G.F. Fleming A phase 2 study of AZD2171 in recurrent or persistent ovarian, peritoneal or fallopian tube cancer. A study of the PMH, Chicago, and California Phase II Consortia Mol Cancer Ther 6 2007 abst. B2
27. R.J. Motzer, T.E. Hutson, and P. Tomczak Sunitinib versus interferon alfa in metastatic renal-cell carcinoma N Engl J Med 356 2007 115 124 (Pubitemid 46089672)
28. L.F. Kontovinis, K.T. Papazisis, and P. Touplikioti Sunitinib treatment for patients with clear-cell metastatic renal cell carcinoma: clinical outcomes and plasma angiogenesis markers BMC Cancer 9 2009 82
29. B.I. Rini, M.D. Michaelson, and J.E. Rosenberg Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma J Clin Oncol 26 2008 3743 3748